Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

A Trial Evaluating Two Imetelstat Doses in Participants With Lower Risk Myelodysplastic Syndrome (MDS) (OptIMize)

9 listopada 2026 zaktualizowane przez: Geron Corporation

A Randomized, Single-Blind, Multicenter Phase 4 Trial Evaluating Two Imetelstat Doses in Participants With Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS)

This study is testing two doses of imetelstat in adults with lower-risk myelodysplastic syndrome, or MDS. The study will include about 100 adults in several countries. To be eligible, participants must have lower-risk MDS, need frequent red blood cell transfusions, and have already tried-or cannot use-other treatments for anemia. Participants will be randomly placed into one of two groups. One group will receive the usual dose of imetelstat, 7.1 mg/kg of body weight. The other group will receive a lower dose, 3.55 mg/kg. Both doses are given through a vein during a roughly two-hour clinic visit every four weeks. Participants won't be told which dose they receive, but their study doctors and the study sponsor will know.

The main goal is to learn whether the lower dose can be safer while still reducing transfusion needs.

Blood tests will be done often, especially early in treatment. If blood counts fall too much or other serious side effects occur, treatment may be delayed, lowered, or stopped. Participants in the lower-dose group who have no clear benefit after at least six treatment cycles may be allowed to move to the higher dose if they meet safety requirements. Study treatment can continue until the disease gets worse, side effects become too severe, patient chooses to stop, or the study ends. Study visits include blood tests, physical exams, vital signs, reviews of transfusions and side effects, and sometimes cardiac or bone marrow tests. Investigators will also collect extra blood samples to study imetelstat pharmacokinetic and how it affects blood cells and MDS-related genes.

Taking part is voluntary. Participants may leave the study at any time.

Przegląd badań

Typ studiów

Interwencyjne

Zapisy (Szacowany)

100

Faza

  • Faza 4

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Kopia zapasowa kontaktu do badania

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Man or woman greater than or equal to (≥) 18 years of age
  • Diagnosis of MDS according to World Health Organization (WHO) 2016 classification confirmed by bone marrow aspirate and biopsy within 6 months prior to randomization that meets revised IPSS-R classification of very low, low, or intermediate risk disease
  • RBC transfusion dependent, defined as requiring at least 4 RBC units transfused over an 8-week period during the 16 weeks prior to randomization; pre-transfusion Hgb should be ≤ 9.0 g/dL to count towards the 4 units total.
  • Relapsed/refractory to, or ineligible for, erythropoiesis-stimulating agent (ESA) (EPO levels > 500 or per local guidelines); or Relapsed/refractory to, or ineligible for, erythroid maturation agent (EMA) (such as luspatercept) and has an endogenous serum EPO level >200 mU/mL at time of screening.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2

Exclusion Criteria:

  • Participant has known allergies, hypersensitivity, or intolerance to imetelstat or its excipients
  • Prior treatment with imetelstat
  • Participant has received an experimental or investigational drug or used an invasive investigational medical device within 30 days of randomization
  • Has received corticosteroids greater than (>) 30 milligram per day (mg/day) prednisone or equivalent within 4 weeks prior to randomization, or growth factor treatment for a 7-day period or 7 half-lives of growth factor used prior to randomization, whichever is longer.
  • Has received ESA or EMA therapy within 4 weeks prior to randomization (8 weeks for long-acting ESAs) or any chemotherapy, immunomodulatory or immunosuppressive therapy, within 4 weeks prior to randomization

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Pojedynczy

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Inny: Arm A: imetelstat 7.1 mg/kg

Participants will receive imetelstat at 7.1 mg/kg intravenous (IV) every 28 days (±3 days), until disease progression or unacceptable toxicity, withdrawal from treatment or end of study.

imetelstat will be given intravenously at 7.1 mg/kg intravenous (IV) every 28 days (±3 days), until disease progression or unacceptable toxicity, withdrawal from treatment or end of study.

Eksperymentalny: Arm B: imetelstat 3.55 mg/kg

Participants will receive imetelstat at 3.55 mg/kg intravenous (IV) every 28days (±3 days), until disease progression or unacceptable toxicity, withdrawal of treatment or end of study.

imetelstat will be given intravenously at 3.55 mg/kg intravenous (IV) every 28 days (±3 days), until disease progression or unacceptable toxicity, withdrawal from treatment or end of study.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Rate of ≥ 12-week Red Blood Cell Transfusion Independence (RBC TI) with concurrent mean Hgb rise of at least 1.5 g/dL
Ramy czasowe: Weeks 1-24

Proportion of participants who do not have any RBC transfusion with concurrent mean Hgb rise of at least 1.5 g/dL during any consecutive 12 weeks (84 days) starting from randomization until subsequent anticancer therapy or dose escalation if any

Weeks 1-24
Rate of Grade 3/4 thrombocytopenia by laboratory values
Ramy czasowe: Weeks 1-24

Proportion of participants who had at least one dose of trial treatment and who had experienced Grade 3 or Grade 4 thrombocytopenia events by laboratory values before subsequent anticancer therapy or dose escalation if any

Weeks 1-24

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Rate of ≥ 12 weeks RBC TI
Ramy czasowe: Weeks 1-24

Proportion of participants without any RBC transfusion during any consecutive 12 weeks (84 days) starting from randomization until subsequent anticancer therapy or dose escalation if any

Weeks 1-24
Rate of ≥ 12 weeks RBC TI with concurrent mean Hgb rise of at least 1.5 g/dL
Ramy czasowe: Up to End of Study (approximately 3.5 years)

It is defined as the proportion of participants who do not have any RBC transfusion with concurrent mean Hgb rise of at least 1.5 g/dL during any consecutive 12 weeks (84 days) at any time starting from randomization until subsequent anticancer therapy or dose escalation if any.

Up to End of Study (approximately 3.5 years)
Rate of RBC TI ≥ 8 weeks, ≥12 weeks, ≥ 16 weeks, or ≥ 24 weeks
Ramy czasowe: Up to End of Study (approximately 3.5 years)

Proportion of participants without any RBC transfusion during any consecutive 8, 12, 16, or 24 weeks (56, 84, 112, or 168 days) respectively at any time starting from randomization until subsequent anti-cancer therapy or dose escalation if any

Up to End of Study (approximately 3.5 years)
Duration of RBC TI Response
Ramy czasowe: Up to End of Study (approximately 3.5 years)

Duration of RBC TI defined as the first day of the longest RBC TI period to the date of the first RBC transfusion after the TI period started.

Up to End of Study (approximately 3.5 years)
Time to RBC TI Response
Ramy czasowe: Up to End of Study (approximately 3.5 years)

It is defined as the interval from randomization to the first day of corresponsive RBC TI response

Up to End of Study (approximately 3.5 years)
Hgb peak and rise
Ramy czasowe: Up to End of Study (approximately 3.5 years)

Hgb peak defined as the maximum Hgb value excluding values that were within 14 days after transfusion. Hgb rise defined as the difference between the Hgb peak and the pretreatment Hgb level

Up to End of Study (approximately 3.5 years)
Rate of Hgb rise of at least 1.5 g/dL lasting ≥ 12 weeks
Ramy czasowe: Up to End of Study (approximately 3.5 years)

Defined as the proportion of participants who had Hgb rise lasting at least 12 weeks during any consecutive 12 weeks (84 days) starting from randomization until subsequent anticancer therapy or dose escalation if any

Up to End of Study (approximately 3.5 years)
Rate of Hematologic Improvement Including Erythroid Response (HI-E) as Per International Working Group (IWG) Response Criteria 2018
Ramy czasowe: Up to End of Study (approximately 3.5 years)

For low transfusion burden participants (who received 3 to 7 RBC units in the 16 weeks prior to trial entry): Clinically meaningful HI-E response per revised IWG 2018 is defined as 16-week RBC TI, i.e., participants without any RBC transfusion during any consecutive 16 weeks.

For high transfusion burden participants (who received ≥ 8 RBC units in the 16 weeks prior to trial entry):

  • Major HI-E response per revised IWG 2018 is defined as 16-week RBC TI.
  • Minor HI-E response per revised IWG 2018 is defined as a reduction by at least 50% of RBC units over a 16-week period compared with the 16 weeks prior to trial entry.
Up to End of Study (approximately 3.5 years)
Rate of disease progression, including AML progression
Ramy czasowe: Up to End of Study (approximately 3.5 years)

Proportion of participants who had disease progression (or AML progression) per modified IWG 2006 criteria

Up to End of Study (approximately 3.5 years)
Rate of Grade 3/4 neutropenia by laboratory values
Ramy czasowe: Weeks 1-24

Defined as the proportion of participants who had at least one dose of trial treatment and who had experienced Grade 3 or Grade 4 neutropenia events by laboratory values before subsequent anticancer therapy or dose escalation, if any

Weeks 1-24
Treatment Emergent Adverse Events (TEAEs)
Ramy czasowe: Up to End of Study (approximately 3.5 years)

Incidence, severity, and type of treatment emergent adverse events (TEAEs, with a specific focus on bleeding and infection events), and other clinical laboratory values (including liver function test [LFT] abnormalities)

Up to End of Study (approximately 3.5 years)
Time to Resolution of Lab Events
Ramy czasowe: Up to End of Study (approximately 3.5 years)

Time to resolution of Grade ≥ 3 neutrophil and platelet counts to baseline grade after end of dosing.

Up to End of Study (approximately 3.5 years)
Assessment of Plasma concentrations of imetelstat
Ramy czasowe: Cycles 1-6 (28 day cycles)

Concentrations of imetelstat in Plasma

Cycles 1-6 (28 day cycles)
Assessment of Cmax
Ramy czasowe: Cycles 1-6 (28 day cycles)

Maximum Observed Plasma Concentration (Cmax)

Cycles 1-6 (28 day cycles)
Assessment of AUC
Ramy czasowe: Cycles 1-6 (28 day cycles)

Area under the drug concentration-plasma time curve (AUC) from time zero to last measurable concentration

Cycles 1-6 (28 day cycles)
Population PK/PD Model-Predicted Rates of Grade 3/4 Thrombocytopenia, Grade 3/4 Neutropenia, and Mean ≥1.5 g/dL Hemoglobin Increase Sustained for ≥12 Weeks
Ramy czasowe: Cycles 1-6 (28 day cycles)
Cycles 1-6 (28 day cycles)

Inne miary wyników

Miara wyniku
Opis środka
Ramy czasowe
Time to acute myeloid leukemia (AML) progression among participants with documented AML progression
Ramy czasowe: Up to End of Study (approximately 3.5 years)
Up to End of Study (approximately 3.5 years)
Assessment of biomarkers
Ramy czasowe: Cycles 1-2 (28 day cycles)

At baseline and change from baseline

Cycles 1-2 (28 day cycles)
Assessment of Mutation status
Ramy czasowe: Up to End of Study (approximately 3.5 years)

At baseline and change from baseline including at the time of suspected progression

Up to End of Study (approximately 3.5 years)

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Śledczy

  • Dyrektor Studium: Joseph E Eid, MD, Geron Corporation

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

1 marca 2027

Zakończenie podstawowe (Szacowany)

1 lipca 2030

Ukończenie studiów (Szacowany)

1 stycznia 2031

Daty rejestracji na studia

Pierwszy przesłany

3 listopada 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

9 listopada 2026

Pierwszy wysłany (Rzeczywisty)

16 listopada 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

16 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

9 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Tak

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj